Compare CTNT & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTNT | INKT |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 70.6M |
| IPO Year | 2023 | 2021 |
| Metric | CTNT | INKT |
|---|---|---|
| Price | $3.26 | $12.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 168.1M | 47.5K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.74 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,288,536.00 | N/A |
| Revenue This Year | $42.49 | N/A |
| Revenue Next Year | $22.22 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 182.69 | N/A |
| 52 Week Low | $0.02 | $6.66 |
| 52 Week High | $4.21 | $76.00 |
| Indicator | CTNT | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 75.48 | 54.68 |
| Support Level | $1.48 | $10.94 |
| Resistance Level | N/A | $12.58 |
| Average True Range (ATR) | 0.36 | 1.11 |
| MACD | 0.28 | -0.10 |
| Stochastic Oscillator | 72.54 | 39.33 |
Cheetah Net Supply Chain Service Inc is a provider of logistics and warehousing services, historically in connection with the sale of parallel-import vehicles sourced in the U.S. to be sold in the PRC market, and more recently for the transportation of other goods between the U.S. and the PRC. Parallel-import vehicles in the PRC refer to automobiles purchased directly from overseas markets and imported for sale outside of the brand manufacturer's official distribution networks. The company operates as single report segment. The company operates in the USA and overseas.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.